CN109134568B - 核苷磷酸酯/酰胺衍生物及其医药用途 - Google Patents
核苷磷酸酯/酰胺衍生物及其医药用途 Download PDFInfo
- Publication number
- CN109134568B CN109134568B CN201710450967.3A CN201710450967A CN109134568B CN 109134568 B CN109134568 B CN 109134568B CN 201710450967 A CN201710450967 A CN 201710450967A CN 109134568 B CN109134568 B CN 109134568B
- Authority
- CN
- China
- Prior art keywords
- cancer
- benzo
- oxy
- preparation
- phosphoryl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- -1 Nucleoside phosphate/amide derivatives Chemical class 0.000 title claims abstract description 28
- 239000002777 nucleoside Substances 0.000 title claims abstract description 16
- 150000003839 salts Chemical class 0.000 claims abstract description 7
- 231100000252 nontoxic Toxicity 0.000 claims abstract description 4
- 230000003000 nontoxic effect Effects 0.000 claims abstract description 4
- 238000002360 preparation method Methods 0.000 claims description 32
- 239000008194 pharmaceutical composition Substances 0.000 claims description 4
- 206010028980 Neoplasm Diseases 0.000 claims description 3
- 239000004480 active ingredient Substances 0.000 claims description 3
- 239000003814 drug Substances 0.000 claims description 2
- 239000003937 drug carrier Substances 0.000 claims description 2
- 208000032839 leukemia Diseases 0.000 claims description 2
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 2
- 201000011510 cancer Diseases 0.000 claims 2
- 206010004593 Bile duct cancer Diseases 0.000 claims 1
- 206010005003 Bladder cancer Diseases 0.000 claims 1
- 206010006187 Breast cancer Diseases 0.000 claims 1
- 208000026310 Breast neoplasm Diseases 0.000 claims 1
- 206010009944 Colon cancer Diseases 0.000 claims 1
- 208000001333 Colorectal Neoplasms Diseases 0.000 claims 1
- 208000008839 Kidney Neoplasms Diseases 0.000 claims 1
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims 1
- 206010025323 Lymphomas Diseases 0.000 claims 1
- 206010033128 Ovarian cancer Diseases 0.000 claims 1
- 206010061535 Ovarian neoplasm Diseases 0.000 claims 1
- 229910019142 PO4 Inorganic materials 0.000 claims 1
- 206010061902 Pancreatic neoplasm Diseases 0.000 claims 1
- 206010060862 Prostate cancer Diseases 0.000 claims 1
- 208000000236 Prostatic Neoplasms Diseases 0.000 claims 1
- 206010038389 Renal cancer Diseases 0.000 claims 1
- 208000007097 Urinary Bladder Neoplasms Diseases 0.000 claims 1
- 208000002495 Uterine Neoplasms Diseases 0.000 claims 1
- 150000001408 amides Chemical class 0.000 claims 1
- 208000026900 bile duct neoplasm Diseases 0.000 claims 1
- 208000006990 cholangiocarcinoma Diseases 0.000 claims 1
- 201000010982 kidney cancer Diseases 0.000 claims 1
- 201000007270 liver cancer Diseases 0.000 claims 1
- 208000014018 liver neoplasm Diseases 0.000 claims 1
- 201000005202 lung cancer Diseases 0.000 claims 1
- 208000020816 lung neoplasm Diseases 0.000 claims 1
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 claims 1
- 201000002528 pancreatic cancer Diseases 0.000 claims 1
- 208000008443 pancreatic carcinoma Diseases 0.000 claims 1
- 239000010452 phosphate Substances 0.000 claims 1
- 201000005112 urinary bladder cancer Diseases 0.000 claims 1
- 206010046766 uterine cancer Diseases 0.000 claims 1
- 125000004432 carbon atom Chemical group C* 0.000 abstract description 16
- 125000000217 alkyl group Chemical group 0.000 abstract description 9
- 125000000753 cycloalkyl group Chemical group 0.000 abstract description 4
- 239000012453 solvate Substances 0.000 abstract description 3
- 125000001369 canonical nucleoside group Chemical group 0.000 abstract description 2
- 125000004437 phosphorous atom Chemical group 0.000 abstract 1
- 125000001424 substituent group Chemical group 0.000 abstract 1
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 63
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 42
- 125000005605 benzo group Chemical group 0.000 description 35
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 28
- 238000003756 stirring Methods 0.000 description 27
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 24
- 239000000243 solution Substances 0.000 description 24
- 238000000034 method Methods 0.000 description 22
- 238000005481 NMR spectroscopy Methods 0.000 description 19
- 239000000543 intermediate Substances 0.000 description 19
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 18
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 18
- 229910052739 hydrogen Inorganic materials 0.000 description 18
- 239000001257 hydrogen Substances 0.000 description 18
- 238000001228 spectrum Methods 0.000 description 18
- 238000006243 chemical reaction Methods 0.000 description 14
- 238000001704 evaporation Methods 0.000 description 14
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 13
- 238000001914 filtration Methods 0.000 description 12
- ODKNJVUHOIMIIZ-RRKCRQDMSA-N floxuridine Chemical compound C1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)C(F)=C1 ODKNJVUHOIMIIZ-RRKCRQDMSA-N 0.000 description 12
- XHXFXVLFKHQFAL-UHFFFAOYSA-N phosphoryl chloride Substances ClP(Cl)(Cl)=O XHXFXVLFKHQFAL-UHFFFAOYSA-N 0.000 description 12
- 239000000706 filtrate Substances 0.000 description 10
- 239000012046 mixed solvent Substances 0.000 description 10
- 238000005406 washing Methods 0.000 description 9
- SDUQYLNIPVEERB-QPPQHZFASA-N gemcitabine Chemical compound O=C1N=C(N)C=CN1[C@H]1C(F)(F)[C@H](O)[C@@H](CO)O1 SDUQYLNIPVEERB-QPPQHZFASA-N 0.000 description 8
- 206010067125 Liver injury Diseases 0.000 description 7
- 231100000753 hepatic injury Toxicity 0.000 description 7
- 241000699670 Mus sp. Species 0.000 description 6
- 238000010511 deprotection reaction Methods 0.000 description 6
- 229960005277 gemcitabine Drugs 0.000 description 6
- 239000007787 solid Substances 0.000 description 6
- 230000000259 anti-tumor effect Effects 0.000 description 5
- 150000001875 compounds Chemical class 0.000 description 5
- NHTKGYOMICWFQZ-BBOXMAMFSA-N fosgemcitabine palabenamide Chemical compound C[C@H](N[P@](=O)(OC[C@H]1O[C@@H](N2C=CC(N)=NC2=O)C(F)(F)[C@@H]1O)OC1=CC=CC=C1)C(=O)OCC1=CC=CC=C1 NHTKGYOMICWFQZ-BBOXMAMFSA-N 0.000 description 5
- 239000007924 injection Substances 0.000 description 5
- 238000002347 injection Methods 0.000 description 5
- 229940087646 methanolamine Drugs 0.000 description 5
- 239000000203 mixture Substances 0.000 description 5
- XKRFYHLGVUSROY-UHFFFAOYSA-N Argon Chemical compound [Ar] XKRFYHLGVUSROY-UHFFFAOYSA-N 0.000 description 4
- CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 4
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 4
- BZLVMXJERCGZMT-UHFFFAOYSA-N Methyl tert-butyl ether Chemical compound COC(C)(C)C BZLVMXJERCGZMT-UHFFFAOYSA-N 0.000 description 4
- BIOWRMNRHMERIO-ZVAHOJSLSA-N benzyl (2s)-2-[[[(2r,3s,5r)-5-(5-fluoro-2,4-dioxopyrimidin-1-yl)-3-hydroxyoxolan-2-yl]methoxy-naphthalen-1-yloxyphosphoryl]amino]propanoate Chemical compound N1([C@@H]2O[C@@H]([C@H](C2)O)COP(=O)(N[C@@H](C)C(=O)OCC=2C=CC=CC=2)OC=2C3=CC=CC=C3C=CC=2)C=C(F)C(=O)NC1=O BIOWRMNRHMERIO-ZVAHOJSLSA-N 0.000 description 4
- 210000004027 cell Anatomy 0.000 description 4
- 238000001816 cooling Methods 0.000 description 4
- 230000000694 effects Effects 0.000 description 4
- 238000011156 evaluation Methods 0.000 description 4
- CQRPUKWAZPZXTO-UHFFFAOYSA-M magnesium;2-methylpropane;chloride Chemical compound [Mg+2].[Cl-].C[C-](C)C CQRPUKWAZPZXTO-UHFFFAOYSA-M 0.000 description 4
- 238000002844 melting Methods 0.000 description 4
- 230000008018 melting Effects 0.000 description 4
- 239000003208 petroleum Substances 0.000 description 4
- 239000011541 reaction mixture Substances 0.000 description 4
- 238000010898 silica gel chromatography Methods 0.000 description 4
- 239000002904 solvent Substances 0.000 description 4
- MSWZFWKMSRAUBD-GASJEMHNSA-N 2-amino-2-deoxy-D-galactopyranose Chemical compound N[C@H]1C(O)O[C@H](CO)[C@H](O)[C@@H]1O MSWZFWKMSRAUBD-GASJEMHNSA-N 0.000 description 3
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 3
- LKIFGKNBZDGLOI-SZEHBUNVSA-N [(2r,3r,5r)-5-(4-amino-2-oxopyrimidin-1-yl)-4,4-difluoro-2-(hydroxymethyl)oxolan-3-yl] tert-butyl carbonate Chemical compound FC1(F)[C@H](OC(=O)OC(C)(C)C)[C@@H](CO)O[C@H]1N1C(=O)N=C(N)C=C1 LKIFGKNBZDGLOI-SZEHBUNVSA-N 0.000 description 3
- MSWZFWKMSRAUBD-UHFFFAOYSA-N beta-D-galactosamine Natural products NC1C(O)OC(CO)C(O)C1O MSWZFWKMSRAUBD-UHFFFAOYSA-N 0.000 description 3
- 229960000961 floxuridine Drugs 0.000 description 3
- 239000003826 tablet Substances 0.000 description 3
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 3
- XBNGYFFABRKICK-UHFFFAOYSA-N 2,3,4,5,6-pentafluorophenol Chemical compound OC1=C(F)C(F)=C(F)C(F)=C1F XBNGYFFABRKICK-UHFFFAOYSA-N 0.000 description 2
- HFEKDTCAMMOLQP-RRKCRQDMSA-N 5-fluorodeoxyuridine monophosphate Chemical compound O1[C@H](COP(O)(O)=O)[C@@H](O)C[C@@H]1N1C(=O)NC(=O)C(F)=C1 HFEKDTCAMMOLQP-RRKCRQDMSA-N 0.000 description 2
- GHASVSINZRGABV-UHFFFAOYSA-N Fluorouracil Chemical compound FC1=CNC(=O)NC1=O GHASVSINZRGABV-UHFFFAOYSA-N 0.000 description 2
- YMOXEIOKAJSRQX-QPPQHZFASA-N Gemcitabine triphosphate Chemical compound O=C1N=C(N)C=CN1[C@H]1C(F)(F)[C@H](O)[C@@H](COP(O)(=O)OP(O)(=O)OP(O)(O)=O)O1 YMOXEIOKAJSRQX-QPPQHZFASA-N 0.000 description 2
- IJMWOMHMDSDKGK-UHFFFAOYSA-N Isopropyl propionate Chemical compound CCC(=O)OC(C)C IJMWOMHMDSDKGK-UHFFFAOYSA-N 0.000 description 2
- 238000012449 Kunming mouse Methods 0.000 description 2
- XBDQKXXYIPTUBI-UHFFFAOYSA-N Propionic acid Chemical compound CCC(O)=O XBDQKXXYIPTUBI-UHFFFAOYSA-N 0.000 description 2
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 2
- 102000003929 Transaminases Human genes 0.000 description 2
- 108090000340 Transaminases Proteins 0.000 description 2
- DTQVDTLACAAQTR-UHFFFAOYSA-N Trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 2
- 239000002246 antineoplastic agent Substances 0.000 description 2
- 229940041181 antineoplastic drug Drugs 0.000 description 2
- 229910052786 argon Inorganic materials 0.000 description 2
- RLMHWGDKMJIEHH-QRPNPIFTSA-N benzyl (2s)-2-aminopropanoate;hydrochloride Chemical compound Cl.C[C@H](N)C(=O)OCC1=CC=CC=C1 RLMHWGDKMJIEHH-QRPNPIFTSA-N 0.000 description 2
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 description 2
- 210000004369 blood Anatomy 0.000 description 2
- 239000008280 blood Substances 0.000 description 2
- 229910002092 carbon dioxide Inorganic materials 0.000 description 2
- 239000001569 carbon dioxide Substances 0.000 description 2
- 239000012230 colorless oil Substances 0.000 description 2
- 238000001035 drying Methods 0.000 description 2
- 239000000284 extract Substances 0.000 description 2
- 239000012065 filter cake Substances 0.000 description 2
- 229960002949 fluorouracil Drugs 0.000 description 2
- 238000000227 grinding Methods 0.000 description 2
- 238000010438 heat treatment Methods 0.000 description 2
- 230000005764 inhibitory process Effects 0.000 description 2
- 239000012452 mother liquor Substances 0.000 description 2
- 238000000465 moulding Methods 0.000 description 2
- IZUPBVBPLAPZRR-UHFFFAOYSA-N pentachloro-phenol Natural products OC1=C(Cl)C(Cl)=C(Cl)C(Cl)=C1Cl IZUPBVBPLAPZRR-UHFFFAOYSA-N 0.000 description 2
- QDQVXVRZVCTVHE-YFKPBYRVSA-N propan-2-yl (2s)-2-aminopropanoate Chemical compound CC(C)OC(=O)[C@H](C)N QDQVXVRZVCTVHE-YFKPBYRVSA-N 0.000 description 2
- 210000002966 serum Anatomy 0.000 description 2
- 239000007929 subcutaneous injection Substances 0.000 description 2
- 238000010254 subcutaneous injection Methods 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 238000004808 supercritical fluid chromatography Methods 0.000 description 2
- DYHSDKLCOJIUFX-UHFFFAOYSA-N tert-butoxycarbonyl anhydride Chemical compound CC(C)(C)OC(=O)OC(=O)OC(C)(C)C DYHSDKLCOJIUFX-UHFFFAOYSA-N 0.000 description 2
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 2
- RLIHXKPTGKETCC-QMMMGPOBSA-N (2s)-2-(benzylazaniumyl)propanoate Chemical compound OC(=O)[C@H](C)NCC1=CC=CC=C1 RLIHXKPTGKETCC-QMMMGPOBSA-N 0.000 description 1
- DATPFTPVGIHCCM-BYPYZUCNSA-N (2s)-2-(ethylamino)propanoic acid Chemical compound CCN[C@@H](C)C(O)=O DATPFTPVGIHCCM-BYPYZUCNSA-N 0.000 description 1
- RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 description 1
- 238000002965 ELISA Methods 0.000 description 1
- UIOFUWFRIANQPC-JKIFEVAISA-N Floxacillin Chemical compound N([C@@H]1C(N2[C@H](C(C)(C)S[C@@H]21)C(O)=O)=O)C(=O)C1=C(C)ON=C1C1=C(F)C=CC=C1Cl UIOFUWFRIANQPC-JKIFEVAISA-N 0.000 description 1
- 241001529936 Murinae Species 0.000 description 1
- 235000019483 Peanut oil Nutrition 0.000 description 1
- LUSZGTFNYDARNI-UHFFFAOYSA-N Sesamol Natural products OC1=CC=C2OCOC2=C1 LUSZGTFNYDARNI-UHFFFAOYSA-N 0.000 description 1
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
- FZWLAAWBMGSTSO-UHFFFAOYSA-N Thiazole Chemical compound C1=CSC=N1 FZWLAAWBMGSTSO-UHFFFAOYSA-N 0.000 description 1
- 238000002835 absorbance Methods 0.000 description 1
- 125000003118 aryl group Chemical group 0.000 description 1
- 230000003385 bacteriostatic effect Effects 0.000 description 1
- YGYLYUIRSJSFJS-QMMMGPOBSA-N benzyl (2s)-2-aminopropanoate Chemical compound C[C@H](N)C(=O)OCC1=CC=CC=C1 YGYLYUIRSJSFJS-QMMMGPOBSA-N 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 239000012267 brine Substances 0.000 description 1
- 239000006189 buccal tablet Substances 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 238000013270 controlled release Methods 0.000 description 1
- 239000013078 crystal Substances 0.000 description 1
- BYAGYQXRLBVKTP-ZETCQYMHSA-N cyclohexyl (2s)-2-aminopropanoate Chemical compound C[C@H](N)C(=O)OC1CCCCC1 BYAGYQXRLBVKTP-ZETCQYMHSA-N 0.000 description 1
- WVPKAWVFTPWPDB-UHFFFAOYSA-M dichlorophosphinate Chemical compound [O-]P(Cl)(Cl)=O WVPKAWVFTPWPDB-UHFFFAOYSA-M 0.000 description 1
- TXFOLHZMICYNRM-UHFFFAOYSA-N dichlorophosphoryloxybenzene Chemical compound ClP(Cl)(=O)OC1=CC=CC=C1 TXFOLHZMICYNRM-UHFFFAOYSA-N 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 239000008298 dragée Substances 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 230000003028 elevating effect Effects 0.000 description 1
- 230000008020 evaporation Effects 0.000 description 1
- 239000007941 film coated tablet Substances 0.000 description 1
- 229960005144 gemcitabine hydrochloride Drugs 0.000 description 1
- 239000001963 growth medium Substances 0.000 description 1
- 239000007902 hard capsule Substances 0.000 description 1
- 239000012729 immediate-release (IR) formulation Substances 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 230000005918 in vitro anti-tumor Effects 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 239000007928 intraperitoneal injection Substances 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 210000004698 lymphocyte Anatomy 0.000 description 1
- 239000008176 lyophilized powder Substances 0.000 description 1
- 239000004005 microsphere Substances 0.000 description 1
- 150000003833 nucleoside derivatives Chemical class 0.000 description 1
- 239000002773 nucleotide Substances 0.000 description 1
- 239000000312 peanut oil Substances 0.000 description 1
- 150000003013 phosphoric acid derivatives Chemical class 0.000 description 1
- 239000002504 physiological saline solution Substances 0.000 description 1
- 239000011148 porous material Substances 0.000 description 1
- 229920006395 saturated elastomer Polymers 0.000 description 1
- 239000000741 silica gel Substances 0.000 description 1
- 229910002027 silica gel Inorganic materials 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- HPALAKNZSZLMCH-UHFFFAOYSA-M sodium;chloride;hydrate Chemical compound O.[Na+].[Cl-] HPALAKNZSZLMCH-UHFFFAOYSA-M 0.000 description 1
- 239000007901 soft capsule Substances 0.000 description 1
- 239000006190 sub-lingual tablet Substances 0.000 description 1
- 239000007940 sugar coated tablet Substances 0.000 description 1
- 239000007939 sustained release tablet Substances 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 210000004881 tumor cell Anatomy 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
- C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
- C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
- C07H19/06—Pyrimidine radicals
- C07H19/10—Pyrimidine radicals with the saccharide radical esterified by phosphoric or polyphosphoric acids
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Biochemistry (AREA)
- Biotechnology (AREA)
- General Health & Medical Sciences (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Saccharide Compounds (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Description
技术领域
本发明涉及具有抗肿瘤作用的核苷磷酸酯/酰胺衍生物及其异构体。
背景技术
肿瘤是严重威胁人类健康的重大疾病。吉西他滨(Gemcitabine,化学名 2’,2’-二氟-2’-脱氧胞嘧啶核苷)及5-氟尿嘧啶(5-fluorouracil)是临床最常用 的两种抗肿瘤药物。吉西他滨和5-氟尿嘧啶分别在细胞内转化为2’,2’-二氟 -2’-脱氧胞嘧啶核苷三磷酸(dFdCTP)和5-氟脱氧尿嘧啶核苷单磷酸 (5-FdUMP)发挥抗肿瘤作用。
文献报道吉西他滨和5-氟脱氧尿嘧啶核苷的核苷磷酸酯/酰胺衍生物 NUC-1031和NUC-3073分别具有比吉西他滨和5-氟脱氧尿嘧啶核苷更强的抗 肿瘤活性,但是NUC-1031和NUC-3073具有升高转氨酶的肝脏副作用。
发明内容
本发明提供式I所示的核苷磷酸酯/酰胺衍生物,及其非毒性药学上可接 受的盐:
式I中,Nu代表如下解结构的核苷残基:
R1选自碳原子数1-5的烷基、碳原子数1-7的环烷基、或碳原子数1-8的 芳香烷基;R2选自H或碳原子数1-5的烷基。
当Nu为吉西他滨,即2’,2’-二氟-2’-脱氧胞嘧啶核苷残基时,本发明进一 步提供式Ia所示的核苷磷酸酯/酰胺衍生物,及其非毒性药学上可接受的盐:
式Ia中,R1选自碳原子数1-5的烷基、碳原子数1-7的环烷基、或碳原子 数1-8的芳香烷基;R2选自H或碳原子数1-5的烷基。
当Nu为5-氟脱氧尿嘧啶核苷残基时,本发明进一步提供式Ib所示的核 苷磷酸酯/酰胺衍生物,及其非毒性药学上可接受的盐:
式Ib中,R1选自碳原子数1-5的烷基、碳原子数1-7的环烷基、或碳原 子数1-8的芳香烷基;R2选自H或碳原子数1-5的烷基。
本专利发明人意外发现,式I、Ia及Ib所示的核苷磷酸酯/酰胺衍生物 的不同异构体具有不同的抗肿瘤活性。因此,本发明进一步提供式Ia和Ib 的S-异构体Sp-Ia和Sp-Ib:
式Sp-Ia和Sp-Ib中,R1和R2的定义同上。
本发明也进一步提供式Ia和Ib的R-异构体Rp-Ia和Rp-Ib:
式Rp-Ia和Rp-Ib中,R1和R2的定义同上。
具体地,本发明提供的化合物选自如下结构:
本发明提供式I、Ia、Ib、Sp-Ia、Sp-Ib、Rp-Ia及Rp-Ib所示的核苷磷酸酯 /酰胺衍生物或其药学上可接受的盐或其溶剂合物作为活性成分,以及一种或 多种药用载体或赋形剂的药物组合物。
本发明提供式I、Ia、Ib、Sp-Ia、Sp-Ib、Rp-Ia及Rp-Ib所示的核苷磷酸酯 /酰胺衍生物或其药学上可接受的盐或其溶剂合物作为活性成分,及其药物组 合物在制备抗肿瘤药物中的用途;这些药物组合物可以是片剂,如速释片、缓 释片、控释片、薄膜衣片、糖衣片、口含片、舌下片、等;胶囊剂如硬胶囊 剂、软胶囊剂等;注射剂如无菌的或含抑菌剂的水性注射液、油性注射液、 冷冻干燥粉针剂、注射用微球等。
发明人意外地发现,式I、Ia、Ib、Sp-Ia、Sp-Ib、Rp-Ia及Rp-Ib所示的 核苷磷酸酯/酰胺衍生物口服给药后,能够抑制肝损伤所引起的转氨酶升高。
具体实施方式
下述实施例用于具体地解释本发明,然而本发明的范围并不限于下述实施 例。
参考实施例1 5’-[苯氧基-((S)-(1-苯甲氧基羰基-)乙胺基)-磷酰基]-2’,2’-二氟-2’-脱氧胞嘧啶核苷(NUC-1031)的制备
参考实施例1.1 3’-O-(叔丁基氧基羰基)-2’,2’-二氟-2’-脱氧胞嘧啶核苷(i-1)的制备
在80mL二氧六环和20mL水的混合溶剂中,加入6g吉西他滨盐酸盐, 11g Na2CO3,搅拌下加入4.4g二叔丁基二碳酸酯,室温搅拌24小时,加入 200ml水,用乙酸乙酯(600mlX2)提取,合并提取液,依次用100ml水和100ml 盐水洗,用无水硫酸钠干燥;过滤,将滤液减压蒸干;将残留物用硅胶柱层 析分离,用二氯甲烷∶甲醇(10∶1)洗脱,收集所需组分,减压蒸干,得中间 体i-1 5.8g。
参考实施例1.2苯氧基-((S)-(1-苯甲氧基羰基-)乙胺基)-磷酰氯(ii-1)的制备
将2.1克二氯磷酸苯酚酯和2.2克L-丙氨酸苄酯盐酸盐溶于30mL无水二 氯甲烷中,冷却至-78℃。搅拌下滴加2ml三乙胺溶于20mL无水二氯甲烷的 溶液,控制滴加速度以保持反应温度-78℃。加完后,待反应温度缓升至室温, 继续搅拌1小时。减压蒸出溶剂,在残留物中加入30ml无水乙醚,过滤。将 滤液减压蒸干,得中间体ii-1,直接用于下步反应。
参考实施例1.3 5’-[苯氧基-((S)-(1-苯甲氧基羰基-)乙胺基)-磷酰基]- 3’-O-(叔丁基氧基羰基)-2’,2’-二氟-2’-脱氧胞嘧啶核苷(iii-1)的制备
将0.36克i-1溶于10mL干燥的四氢呋喃,加入1ml 1M叔特丁基氯化 镁的THF溶液,搅拌0.5h,搅拌下加入0.7g ii-1溶于2ml THF的溶液,搅拌 12h。减压蒸干,将残留物用硅胶柱层析分离,用二氯甲烷∶甲醇∶三乙胺 (100∶5∶1)混合溶剂洗脱,收集所需组分,蒸干后得到中间体iii-1 0.24g。
参考实施例1.4 5’-[苯氧基-((S)-(1-苯甲氧基羰基-)乙胺基)-磷酰基]- -2’,2’- 二氟-2’-脱氧胞嘧啶核苷(NUC-1031)的制备
在3ml二氯甲烷中,加入3ml三氟乙酸,搅拌冷却至0℃;加入0.24g iii-1, 搅拌反应3小时。减压蒸干,加入5ml饱和NaHCO3溶液,用乙酸乙酯提取 (10ml X 2),合并提取液,用无水硫酸钠干燥后,减压蒸干,用二氯甲烷∶ 甲醇∶三乙胺(100∶5∶1)混合溶剂洗脱,收集所需组分,蒸干后得到NUC-1031 0.13g。核磁共振氢谱δ(ppm,MeOD):7.57(d,0.5H),7.53(d,0.5H),7.40-7.34 (m,7H),7.28-7.21(m,3H),6.26(m,1H),5.89(d,0.5H),5.85(d,0.5H), 5.19-5.13(m,2H),4.51-4.32(m,2H),4.26-4.18(m,1H),4.08-4.02(m,2H), 1.39(m,3H)。
参考实施例2 5’-[1-萘氧基-((S)-(1-苯甲氧基羰基-)乙胺基)-磷酰基]- 5-氟-2’-脱氧尿嘧啶核苷(NUC-3073)的制备
参考实施例2.1 1-萘氧基-((S)-(1-苯甲氧基羰基-)乙胺基)-磷酰氯(ii-2)的制备
将2.3克二氯磷酸萘酚酯和2.2克L-丙氨酸苄酯盐酸盐溶于30mL无水二 氯甲烷中,冷却至-78℃。搅拌下滴加2ml三乙胺溶于20mL无水二氯甲烷的 溶液,控制滴加速度以保持反应温度-78℃。加完后,待反应温度缓升至室温, 继续搅拌1小时。减压蒸出溶剂,在残留物中加入30ml无水乙醚,过滤。将 滤液减压蒸干,得中间体ii-2,直接用于下步反应。
参考实施例2.2 5’-[1-萘氧基-((S)-(1-苯甲氧基羰基-)乙胺基)-磷酰基]- 5-氟 -2’-脱氧尿嘧啶核苷(NUC-3073)的制备
将0.25克5-氟-2’-脱氧尿嘧啶核苷(5-FdU)溶于10mL干燥的四氢呋喃, 加入1ml1M叔特丁基氯化镁的THF溶液,搅拌0.5h,搅拌下加入0.8g ii-2溶 于2ml THF的溶液,搅拌12h。减压蒸干,将残留物用硅胶柱层析分离,用 二氯甲烷∶甲醇∶三乙胺(100∶5∶1)混合溶剂洗脱,收集所需组分,蒸干后 得到NUC-3073 0.11g。核磁共振氢谱δ(ppm,MeOD):8.17-8.10(m,1H), 7.88-7.85(m,1H),7.71-7.66(m,2H),7.54-7.45(m,3H),7.43-7.25(m,6H),6.12-6.05 (m,1H),5.11-5.07(m,2H),4.35-4.23(m,3H),4.13-4.01(m,2H),2.16-2.07(m,1H), 1.78-1.66(m,1H),1.37-1.33(m,3H)。
实施例1 5’-[(苯并[1,3]二氧五环-5-基)-氧基-((S)-(1-乙氧基羰基-)乙胺基)- 磷酰基]- -2’,2’-二氟-2’-脱氧胞嘧啶核苷(Ia-1)的制备
实施例1.1(苯并[1,3]二氧五环-5-基)-氧基-((S)-(1-乙氧基羰基-)乙胺基)-磷酰氯(ii-3)的制备
将15.3g三氯氧磷和13.8g 5-羟基苯并二氧无环加于250ml无水乙醚溶液 中,氩气保护下,冷却到-78℃,滴加13.4ml三乙胺,加完后在-78℃搅拌 30分钟,然后室温搅拌过夜。过滤,将滤液减压蒸干,得(苯并[1,3]二氧五环 -5-基)-氧基-二氯氧磷备用。
将2.6克(0.01mol)(苯并[1,3]二氧五环-5-基)-氧基-二氯氧磷和1.5克(0.01mol)L-丙氨酸乙酯溶于30mL无水二氯甲烷中,冷却至-78℃。搅拌下滴加 2ml三乙胺溶于20mL无水二氯甲烷的溶液,控制滴加速度以保持反应温度 -78℃。加完后,待反应温度缓升至室温,继续搅拌1小时。减压蒸出溶剂, 在残留物中加入30ml无水乙醚,过滤。将滤液减压蒸干,得ii-3,直接用于 下步反应。
实施例1.2 5’-[(苯并[1,3]二氧五环-5-基)-氧基-((S)-(1-乙氧基羰基-)乙胺基)-磷酰基]- -2’,2’-二氟-2’-脱氧胞嘧啶核苷(Ia-1)的制备
参照实施例1.3的方法,将i-1与ii-3反应,制得中间体iii-2;
参照1.4的方法,将iii-2脱保护,得到Ia-1。核磁共振氢谱δ(ppm,MeOD): 7.58(d,0.5H),7.54(d,0.5H),6.76(d,1H),6.67(s,1H),6.48(d,1H),6.26 (m,1H),5.99(s,2H),5.88(d,0.5H),5.86(d,0.5H),4.56-4.36(m,2H),4.27-4.20 (m,1H),4.10-4.00(m,2H),3.62(m,2H),1.35(m,3H),1.15(m,3H)。
实施例2 5’-[(苯并[1,3]二氧五环-5-基)-氧基-((S)-(1-异丙氧基羰基-)乙胺基)-磷酰基]- -2’,2’-二氟-2’-脱氧胞嘧啶核苷(Ia-2)的制备
参照实施例1.1的方法,将(苯并[1,3]二氧五环-5-基)-氧基-二氯氧磷与L- 丙氨酸异丙酯反应,制得中间体(苯并[1,3]二氧五环-5-基)-氧基-((S)-(1-异丙氧基 羰基-)乙胺基)-磷酰氯(ii-4)。
参照实施例1.3的方法,将i-1与ii-4反应,制得中间体iii-3。
参照1.4的方法,将iii-3脱保护,得到Ia-2。核磁共振氢谱δ(ppm,MeOD): 7.58(d,0.5H),7.53(d,0.5H),6.76(m,1H),6.67(s,1H),6.48(m,1H),6.26 (m,1H),5.99(s,2H),5.88(d,0.5H),5.86(d,0.5H),5.02(m,1H),4.56-4.36 (m,2H),4.27-4.20(m,1H),4.11-4.01(m,1H),1.35(m,3H),1.25-1.22(m, 6H)。
实施例3 5’-[(苯并[1,3]二氧五环-5-基)-氧基-((S)-(1-环己氧基羰基-)乙胺基)-磷酰基]- -2’,2’-二氟-2’-脱氧胞嘧啶核苷(Ia-3)的制备
参照实施例1.1的方法,将(苯并[1,3]二氧五环-5-基)-氧基-二氯氧磷与L- 丙氨酸环己酯反应,制得中间体(苯并[1,3]二氧五环-5-基)-氧基-((S)-(1-环己氧基 羰基-)乙胺基)-磷酰氯(ii-5)。
参照实施例1.3的方法,将i-1与ii-5反应,制得中间体iii-4;
参照1.4的方法,将iii-4脱保护,得到Ia-3。核磁共振氢谱δ(ppm,MeOD): 7.59(d,0.5H),7.55(d,0.5H),6.76(m,1H),6.67(s,1H),6.48(m,1H),6.26 (m,1H),5.99(s,2H),5.87(d,0.5H),5.85(d,0.5H),4.75-4.68(m,1H), 4.56-4.36(m,2H),4.27-4.20(m,1H),4.13-4.08(m,1H),3.94(m,1H), 1.90-1.68(m,4H),1.55-1.50(m,1H),1.35(m,3H),1.40-1.22(m,8H)。
实施例4 5’-[(苯并[1,3]二氧五环-5-基)-氧基-((S)-(1-苯甲氧基羰基-)乙胺基)-磷酰基]- -2’,2’-二氟-2’-脱氧胞嘧啶核苷(Ia-4)的制备
参照实施例1.1的方法,将(苯并[1,3]二氧五环-5-基)-氧基-二氯氧磷与L- 丙氨酸苯甲酯反应,制得中间体(苯并[1,3]二氧五环-5-基)-氧基-((S)-(1-苯甲氧基 羰基-)乙胺基)-磷酰氯(ii-6)。
参照实施例1.3的方法,将i-1与ii-6反应,制得中间体iii-5;
参照1.4的方法,将iii-5脱保护,得到Ia-4。核磁共振氢谱δ(ppm,MeOD): 7.57(d,0.5H),7.53(d,0.5H),7.38-7.35(m,3H),7.25-7.20(m,2H);6.76(d, 1H),6.67(s,1H),6.48(d,1H),6.26(m,1H),5.99(s,2H),5.88(d,0.5H),5.86 (d,0.5H),5.18-5.12(m,2H),4.56-4.36(m,2H),4.27-4.20(m,1H),4.13-4.08 (m,1H),3.94(m,1H),1.35(m,3H)。
实施例5 5’-[(苯并[1,3]二氧五环-5-基)-氧基-((S)-(1-乙氧基羰基-)乙胺基)-磷 酰基]-5-氟-2’-脱氧尿嘧啶核苷(Ib-1)的制备
参照参考实施例2.2的方法,将-氟-2’-脱氧尿嘧啶核苷(5-FdU)与ii-3反 应,制得Ib-1。核磁共振氢谱δ(ppm,MeOD):7.72-7.68(m,1H),6.76(d,1H), 6.67(s,1H),6.48(d,1H),6.12(m,1H),5.99(s,2H),4.36-4.24(m,3H),4.15-4.06 (m,2H),3.62(m,2H),2.17-2.10(m,1H),1.79-1.66(m,1H),1.38-1.35(m,3H), 1.15(m,3H)。
实施例6 5’-[(苯并[1,3]二氧五环-5-基)-氧基-((S)-(1-异丙氧基羰基-)乙胺基)- 磷酰基]-5-氟-2’-脱氧尿嘧啶核苷(Ib-2)的制备
参照参考实施例2.2的方法,将-氟-2’-脱氧尿嘧啶核苷(5-FdU)与ii-4反 应,制得Ib-2。核磁共振氢谱δ(ppm,MeOD):7.72-7.68(m,1H),6.76(d,1H), 6.67(s,1H),6.48(d,1H),6.12(m,1H),5.99(s,2H),5.02(m,1H),4.36-4.24 (m,3H),4.15-4.06(m,2H),2.17-2.10(m,1H),1.79-1.66(m,1H),1.38-1.35(m, 3H),1.25-1.22(m,6H)。
实施例7 5’-[(苯并[1,3]二氧五环-5-基)-氧基-((S)-(1-环己氧基羰基-)乙胺基)- 磷酰基]-5-氟-2’-脱氧尿嘧啶核苷(Ib-3)的制备
参照参考实施例2.2的方法,将-氟-2’-脱氧尿嘧啶核苷(5-FdU)与ii-5反 应,制得Ib-3。核磁共振氢谱δ(ppm,MeOD):7.72-7.68(m,1H),6.76(d,1H), 6.67(s,1H),6.48(d,1H),6.12(m,1H),5.99(s,2H),4.75-4.68(m,1H),4.36-4.24 (m,3H),4.15-4.06(m,2H),2.17-2.10(m,1H),1.90-1.65(m,5H),1.55-1.50(m, 1H),141-1.23(m,11H)。
实施例8 5’-[(苯并[1,3]二氧五环-5-基)-氧基-((S)-(1-苯甲氧基羰基-)乙胺基)- 磷酰基]-5-氟-2’-脱氧尿嘧啶核苷(Ib-4)的制备
参照参考实施例2.2的方法,将-氟-2’-脱氧尿嘧啶核苷(5-FdU)与ii-6反 应,制得Ib-4。核磁共振氢谱δ(ppm,MeOD):7.72-7.68(m,1H),7.38-7.35 (m,3H),7.25-7.20(m,2H);6.76(d,1H),6.67(s,1H),6.48(d,1H),6.12 (m,1H),5.99(s,2H),5.18-5.12(m,2H),4.36-4.24(m,3H),4.15-4.06(m,2H), 2.17-2.10(m,1H),1.79-1.66(m,1H),1.38-1.35(m,3H)。
实施例9 5’-[(S)-(苯并[1,3]二氧五环-5-基)-氧基-((S)-(1-异丙氧基羰基-)乙胺基)-磷酰基]-2’,2’-二氟-2’-脱氧胞嘧啶核苷(Sp-Ia-2)的制备
实施例9.1(S)-2-[-(S)-(2,3,4,5,6-五氟苯氧基)-(苯并[1,3]二氧五环-5-基-氧 基)-磷酰胺]丙酸异丙酯(Sp-iv-1)和(R)-2-[-(S)-(2,3,4,5,6-五氟苯氧基)-(苯并[1,3]二氧五环-5-基-氧基)-磷酰胺]丙酸异丙酯(Rp-iv-1)的制备
参考文献(Ross BS,et al.Synthesis of Diastereomerically PureNucleotide Phosphoramidates J Org Chem 2011,76,8311-8319)方法,制备关键手性 中间体Sp-iv-1和Rp-iv-1。
将15g三氯氧磷和14g芝麻酚加于200ml无水乙醚溶液中,氩气保护下, 冷却到-78℃,滴加13ml三乙胺,加完后在-78℃搅拌30分钟,然后室温 搅拌过夜。过滤,将滤液减压蒸干,得苯并[1,3]二氧五环-5-基)-氧基-二氯氧磷 备用(现制现用)。
将2.6克苯并[1,3]二氧五环-5-基)-氧基-二氯氧磷和1.6克L-丙氨酸异丙酯 溶于30mL无水二氯甲烷中,冷却至-78℃。搅拌下滴加2.8ml三乙胺溶于15 mL无水二氯甲烷的溶液,控制滴加速度以保持反应温度-78℃。加完后,待 反应温度缓升至室温,继续搅拌1小时。然后将反应混合物冷却至0℃,搅拌 下滴加1.84克五氟苯酚和1.4ml三乙胺溶于5mL无水二氯甲烷的溶液;保持 0℃,继续搅拌4小时。过滤,以20ml二氯甲烷洗涤,合并洗滤液,减压蒸干, 得无色油状物。加入特丁基甲醚40ml,研磨,滤去固体,滤饼用少许特丁基 甲醚洗涤,合并洗滤液,减压蒸干。加入石油醚∶乙酸乙酯混合溶剂(10∶1) 50ml加热溶解,冷却至室温析出固体;滤出固体,再用石油醚∶乙酸乙酯混合 溶剂(10∶1)50ml重结晶,得2.5克中间体Sp-iv-1;异构体纯度de 98.6%; 熔点,116-120℃;比旋光度[α]25 D(c 1.00,CHCl3)+8.2;31PNMR δ(ppm, CDCl3):-0.439;3HNMR δ(ppm,DMSO-D6):6.90-6.92(d,1H),6.84(m,1H), 6.70(m,1H),6.00(s,2H),4.86-4.89(m,1H),3.89-3.92(m,1H),1.26-1.28(d, 3H),1.16-1.18(d,6H)。
将富集Rp异构体的母液蒸干,用甲醇溶解(约20mg/ml),用手性柱 (2X15cm)超临界流体色谱分离,35%异丙醇二氧化碳流动相洗脱,压力100 bar,每次上样4ml。收集第一个组分,合并后减压蒸干,放置固化,得到1.9 g中间体Rp--iv-1;de 99.2%;熔点,87-92℃;31PNMR δ(ppm,CDCl3):-0.542; 3HNMRδ(ppm,DMSO-D6,400MHz):6.91-6.93(d,1H),6.85(m,1H),6.71 (m,1H),5.98(s,2H),4.87-4.90(m,1H),3.90-3.93(m,1H),1.27-1.29(d,3H), 1.17-1.20(d,6H)。
实施例9.2 5’-[(S)-(苯并[1,3]二氧五环-5-基)-氧基-((S)-(1-异丙氧基羰基-)乙胺基)-磷酰基]-2’,2’-二氟-2’-脱氧胞嘧啶核苷(Sp-Ia-2)的制 备
将0.66g i-1溶于10ml干燥的THF中,冷却至-5℃,缓慢滴加1.7M的特 丁基氯化镁的THF溶液2.4ml;保持-5℃,搅拌30分钟,然后室温再搅拌 30分钟。将反应混合物冷却至5℃,缓慢滴加1.2克Sp-iv-1溶于10ml THF 的溶液。冰浴下,继续搅拌12小时;减压蒸去THF,将残留物用硅胶柱层析 分离,用二氯甲烷∶甲醇∶三乙胺(100∶5∶1)混合溶剂洗脱,收集所需组分, 蒸干后得到中间体0.47g Sp-iii-3。
参照参考实施例1.4的方法,将Sp-iii-3脱保护,得到0.35g Sp-Ia-2;de 99.2%。核磁共振氢谱δ(ppm,DMSO-D6,400MHz):7.60(d,1H),6.90-6.92(d, 1H),6.84(s,1H),6.70(d,1H),6.26(m,1H),6.00(s,2H),5.90(d,1H), 4.86-4.89(m,1H),4.75-4.70(m,1H),4.38-4.35(m,1H);4.28-4.21(m,1H),3.96 -4.01(m,1H)3.89-3.92(m,1H),1.26-1.28(d,3H),1.16-1.18(d,6H)。
实施例10 5’-[(S)-(苯并[1,3]二氧五环-5-基)-氧基-((S)-(1-苯甲氧基羰基-)乙胺基)-磷酰基]- -2’,2’-二氟-2’-脱氧胞嘧啶核苷(Sp-Ia-4)的制备
实施例10.1(S)-2-[-(S)-(2,3,4,5,6-五氟苯氧基)-(苯并[1,3]二氧五环-5-基-氧 基)-磷酰胺]丙酸苄酯(Sp-iv-2)和(R)-2-[-(S)-(2,3,4,5,6-五氟苯氧基)-(苯并[1,3] 二氧五环-5-基-氧基)-磷酰胺]丙酸苄酯(Rp-iv-2)的制备
将2.6克苯并[1,3]二氧五环-5-基)-氧基-二氯氧磷和1.8克L-丙氨酸苄酯溶 于30mL无水二氯甲烷中,冷却至-78℃。搅拌下滴加2.8ml三乙胺溶于15mL 无水二氯甲烷的溶液,控制滴加速度以保持反应温度-78℃。加完后,待反应 温度缓升至室温,继续搅拌1小时。然后将反应混合物冷却至0℃,搅拌下滴 加1.84克五氟苯酚和1.4ml三乙胺溶于5mL无水二氯甲烷的溶液;保持0℃, 继续搅拌4小时。过滤,以20ml二氯甲烷洗涤,合并洗滤液,减压蒸干,得 无色油状物。加入特丁基甲醚40ml,研磨,滤去固体,滤饼用少许特丁基甲 醚洗涤,合并洗滤液,减压蒸干。加入石油醚∶乙酸乙酯混合溶剂(10∶1)40ml 加热溶解,冷却至室温析出固体;滤出固体,再用石油醚∶乙酸乙酯混合溶剂 (10∶1)30ml重结晶,得2.1克中间体Sp-iv-2;异构体纯度de 98.8%;熔点, 102-123℃;31PNMR δ(ppm,CDCl3):-0.442;3HNMR δ(ppm,DMSO-D6,400 MHz):7.41-7.36(m,3H)7.25-7.22(m,2H)6.90-6.92(d,1H),6.84(m,1H),6.70(m,1H),6.00(s,2H),5.15(s,2H);3.89-3.92(m,1H), 1.26-1.28(d,3H)。
将富集Rp异构体的母液蒸干,用甲醇溶解(约20mg/ml),用手性柱 (2X15cm)超临界流体色谱分离,35%异丙醇二氧化碳流动相洗脱,压力100 bar,每次上样4ml。收集第一个组分,合并后减压蒸干,放置固化,得到1.5 克Rp-iv-2;de 99.3%;熔点,73-90℃;31PNMRδ(ppm,CDCl3):-0.550; 3HNMRδ(ppm,DMSO-D6,400MHz):7.42-7.38(m,3H),7.27-7.23(m,2H), 6.91-6.93(d,1H),6.85(m,1H),6.72(m,1H),6.01(s,2H),5.17(s,2H), 3.88-3.90(m,1H),1.25-1.27(d,3H)。
实施例10.2 5’-[(S)-(苯并[1,3]二氧五环-5-基)-氧基-((S)-(1-苯甲氧基羰基-)乙胺基)-磷酰基]-2’,2’-二氟-2’-脱氧胞嘧啶核苷(Sp-Ia-4)的 制备
将0.66g i-1溶于10ml干燥的THF中,冷却至-5℃,缓慢滴加1.7M的特 丁基氯化镁的THF溶液2.4ml;保持-5℃,搅拌30分钟,然后室温再搅拌 30分钟。将反应混合物冷却至5℃,缓慢滴加1.3克Sp-iv-2溶于10ml THF 的溶液。冰浴下,继续搅拌12小时;减压蒸去THF,将残留物用硅胶柱层析 分离,用二氯甲烷∶甲醇∶三乙胺(100∶5∶1)混合溶剂洗脱,收集所需组分, 蒸干后得到中间体0.41g Sp-iii-5。
参照参考实施例1.4的方法,将Sp-iii-5脱保护,得到0.28g Sp-Ia-4;de 98.5%。核磁共振氢谱δ(ppm,DMSO-D6,400MHz):7.60(d,1H),7.41-7.36(m, 3H),7.25-7.22(m,2H),6.90-6.92(d,1H),6.84(d,1H),6.70(s,1H),6.26 (m,1H),6.00(s,2H),5.90(d,1H),5.15(s,2H),4.75-4.70(m,1H), 4.38-4.35(m,1H),4.28-4.21(m,1H),3.96-4.01(m,1H)3.89-3.92(m,1H), 1.26-1.28(d,3H)。
实施例11 5’-[(R)-(苯并[1,3]二氧五环-5-基)-氧基-((S)-(1-异丙氧基羰基-)乙胺基)-磷酰基]- -2’,2’-二氟-2’-脱氧胞嘧啶核苷(Rp-Ia-2)的制备
参照实施例9.2的方法,将i-1与Rp-iv-1反应,制得中间体Rp-iii-3.
参照参考实施例1.4的方法,将Rp-iii-3脱保护,得到Rp-Ia-2 0.19g;de 99.3%。核磁共振氢谱δ(ppm,DMSO-D6,400MHz):7.60(d,1H),6.90-6.92(d, 1H),6.83(s,1H),6.68(d,1H),6.25(m,1H),5.99(s,2H),5.89(d,1H), 4.85-4.88(m,1H),4.73-4.68(m,1H),4.36-4.32(m,1H);4.26-4.20(m,1H), 3.94-4.01(m,1H),3.87-3.90(m,1H),1.24-1.27(d,3H),1.16-1.18(d, 6H)。
实施例12 5’-[(R)-(苯并[1,3]二氧五环-5-基)-氧基-((S)-(1-苯甲氧基羰基-)乙胺基)-磷酰基]- -2’,2’-二氟-2’-脱氧胞嘧啶核苷(Rp-Ia-4)的制备
参照实施例9.2的方法,将i-1与Rp-iv-2反应,制得中间体Rp-iii-5。
参照参考实施例1.4的方法,将Rp-iii-5脱保护,得到Rp-Ia-4 0.25g;de 99.4%。核磁共振氢谱δ(ppm,DMSO-D6,400MHz):7.61(d,1H),7.41-7.36(m, 3H),7.25-7.22(m,2H),6.90-6.92(d,1H),6.84(d,1H),6.70(s,1H),6.26 (m,1H),5.98(s,2H),5.87(d,1H),5.15(s,2H),4.75-4.70(m,1H), 4.38-4.35(m,1H),4.28-4.21(m,1H),3.96-4.01(m,1H)3.89-3.92(m,1H), 1.25-1.27(d,3H)。
实施例13 5’-[(S)-(苯并[1,3]二氧五环-5-基)-氧基-((S)-(1-异丙氧基羰基-)乙胺基)-磷酰基]-5-氟-2’-脱氧尿嘧啶核苷(Sp-Ib-2)的制备
参照实施例9.2的方法,将5-FdU代替i-1,与Sp-iv-1反应,制得Sp-Ib-2; de98.6%。核磁共振氢谱δ(ppm,DMSO-D6,400MHz):7.72-7.68(m,1H), 6.90-6.92(d,1H),6.84(m,1H),6.70(m,1H),6.12(m,1H),6.00(s,2H), 4.86-4.89(m,1H),4.36-4.24(m,3H),4.12(m,1H),3.89-3.92(m,1H),2.14 (m,1H),1.70(m,1H),1.26-1.28(d,3H),1.16-1.18(d,6H)。
实施例14 5’-[(S)-(苯并[1,3]二氧五环-5-基)-氧基-((S)-(1-苯甲氧基羰基-)乙胺基)-磷酰基]-5-氟-2’-脱氧尿嘧啶核苷(Sp-Ib-4)的制备
参照实施例9.2的方法,将5-FdU代替i-1,与Sp-iv-2反应,制得Sp-Ib-4; de98.4%。核磁共振氢谱δ(ppm,DMSO-D6,400MHz):7.72-7.68(m,1H), 7.41-7.36(m,3H),7.25-7.22(m,2H),6.90-6.92(d,1H),6.84(s,1H),6.70(d, 1H),6.11(m,1H),6.00(s,2H),5.15(s,2H),4.32(m,3H),4.10(m,1H), 3.89-3.92(m,1H),2.12(m,1H),1.72(m,1H),1.26-1.28(d,3H)。
实施例15 5’-[(R)-(苯并[1,3]二氧五环-5-基)-氧基-((S)-(1-异丙氧基羰基-)乙胺基)-磷酰基]-5-氟-2’-脱氧尿嘧啶核苷(Rp-Ib-2)的制备
参照实施例9.2的方法,将5-FdU代替i-1,与Rp-iv-1反应,制得Rp-Ib-2; de99.1%。核磁共振氢谱δ(ppm,DMSO-D6,400MHz):7.70-7.67(m,1H), 6.89-6.91(d,1H),6.82(m,1H),6.70(m,1H),6.12(m,1H),5.99(s,2H), 4.86-4.89(m,1H),4.36-4.24(m,3H),4.12(m,1H),3.89-3.92(m,1H),2.14 (m,1H),1.70(m,1H),1.26-1.28(d,3H),1.16-1.18(d,6H)。
实施例16 5’-[(R)-(苯并[1,3]二氧五环-5-基)-氧基-((S)-(1-苯甲氧基羰基-)乙胺基)-磷酰基]-5-氟-2’-脱氧尿嘧啶核苷(Rp-Ib-4)的制备
参照实施例9.2的方法,将5-FdU代替i-1,与Rp-iv-2反应,制得Rp-Ib-4; de99.3%。核磁共振氢谱δ(ppm,DMSO-D6,400MHz):7.70-7.66(m,1H),7.39 -7.35(m,3H),7.23-7.20(m,2H),6.89-6.92(d,1H),6.82(s,1H),6.69(d,1 H),6.10(m,1H),5.98(s,2H),5.13(s,2H),4.31(m,3H),4.09(m,1H),3.87-3.90 (m,1H),2.11(m,1H),1.70(m,1H),1.26-1.28(d,3H)。
实施例17 体外抗肿瘤活性的评价
分别将鼠白血病细胞L1210和人淋巴细胞CEM细胞接种于96孔板中, 细胞数5x104/孔,置CO2培养箱中孵育至细胞密度达到80%,弃去培养液, 加入含不同浓度待测药物的新培养液,设置3个平行孔;每隔2天更换培养液。 在给药后第3天,加入5mg/mL的噻唑蓝(MTT)溶液10μL/孔,37℃继续 孵育4h,弃液,每孔加入100μL DMSO,室温震荡10min,使MTT结晶完全 溶解。酶联免疫检测仪550nm波长测定每孔吸光度,按公式计算抑制率:
抑制率(%)=(1-受试孔OD值/溶剂对照孔平均OD值)×100%
结果以均值±SD表示,n=3。
由SPSS软件计算各受试物对各种肿瘤细胞生长的半数抑制浓度(IC50)。
表1体外体外抗肿瘤活性评价结果
实施例18 抗CCl4所致小鼠肝损伤作用的评价
昆明种小鼠(20g),随机分组(每组8只)。通过口服给予0.2mmol的待测化 合物;给药1h后,皮下注射0.1%CCl4的花生油溶液(10mL/kg),制备肝损 伤模型;注射生理盐水作为正常对照组。造模后12小时后,再次口服给予 0.2mmol的待测化合物。第二次给药后24小时,采血取血清标本,测定ALT, AST。结果见表2。
表2抗CCl4中毒所致小鼠.肝损伤的作用
实施例19 抗D-氨基半乳糖所致小鼠肝损伤作用的评价
昆明种小鼠(20g),随机分组(每组8只)。通过口服给予0.2mmol的待测化 合物;给药2h后,按750mg/kg的剂量腹腔注射给予D-氨基半乳糖制备肝 损伤模型,皮下注射生理盐水作为正常对照组。造模12h后,再次口服给予 0.2mmol的待测化合物。第二次给药后24小时,采血取血清标本,测定ALT, AST。结果见表3。
表3抗D-氨基半乳糖所致小鼠肝损伤的作用
Claims (3)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201710450967.3A CN109134568B (zh) | 2017-06-15 | 2017-06-15 | 核苷磷酸酯/酰胺衍生物及其医药用途 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201710450967.3A CN109134568B (zh) | 2017-06-15 | 2017-06-15 | 核苷磷酸酯/酰胺衍生物及其医药用途 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN109134568A CN109134568A (zh) | 2019-01-04 |
CN109134568B true CN109134568B (zh) | 2022-11-22 |
Family
ID=64829738
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201710450967.3A Active CN109134568B (zh) | 2017-06-15 | 2017-06-15 | 核苷磷酸酯/酰胺衍生物及其医药用途 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN109134568B (zh) |
Family Cites Families (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB0317009D0 (en) * | 2003-07-21 | 2003-08-27 | Univ Cardiff | Chemical compounds |
CN104151360B (zh) * | 2013-05-14 | 2019-02-22 | 北京美倍他药物研究有限公司 | 磷酸/膦酸衍生物及其医药用途 |
CN106188192B (zh) * | 2015-04-29 | 2019-09-10 | 刘沛 | 含d-氨基酸酯的核苷氨基磷酸/膦酸酯衍生物及其医药用途 |
-
2017
- 2017-06-15 CN CN201710450967.3A patent/CN109134568B/zh active Active
Also Published As
Publication number | Publication date |
---|---|
CN109134568A (zh) | 2019-01-04 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EP3040340B1 (en) | Chemical compounds | |
JP6905609B2 (ja) | 癌の処置のためのウリジンのジオキソラン類似体 | |
KR101759369B1 (ko) | 인을 함유하는 활성물의 입체선택성 합성 | |
US5032680A (en) | 2'-deoxy-5-fluorouridine derivatives | |
KR20160007651A (ko) | 인산/포스폰산 유도체 및 이의 의학적 용도 | |
EA018098B1 (ru) | Фосфинатные соединения (варианты) | |
EP2625187A1 (en) | Phosphoramidite derivatives of gemcitabine for use in the treatment cancer | |
WO2010120112A2 (en) | Novel compounds of reverse-turn mimetics, method for manufacturing the same and use thereof | |
CN109134568B (zh) | 核苷磷酸酯/酰胺衍生物及其医药用途 | |
Lewandowska et al. | Synthesis and anticancer activity of some 5-fluoro-2′-deoxyuridine phosphoramidates | |
AU2019296174B2 (en) | Phosphorus-containing prodrugs of gemcitabine | |
CN108129514A (zh) | 磷酸/膦酸衍生物的单一异构体及其医药用途 | |
KR101231925B1 (ko) | 젬시타빈의 전구약물 및 이의 제조방법 | |
JP2805323B2 (ja) | 2′―デオキシ―5―フルオロウリジン誘導体、その製造方法及びそれを有効成分として含有する抗腫瘍剤 | |
AU2020333099B2 (en) | A prodrug platform useful to deliver amines, amides and phenols | |
GB2627905A (en) | Cordycepin-derivatized compound with anti-tumor effect | |
TW201945378A (zh) | 治療癌症之前藥 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
GR01 | Patent grant | ||
GR01 | Patent grant | ||
TR01 | Transfer of patent right |
Effective date of registration: 20240823 Address after: Room 1208, 12th Floor, Building 3, No. 8 Haiying Road, Fengtai District, Beijing 100070 Patentee after: Beijing Junke Huayuan Pharmaceutical Technology Co.,Ltd. Country or region after: China Address before: 100070 Beijing Fengtai District Branch Road No. nine Room 303 Patentee before: BEIJING MEIBEITA DRUG RES Co.,Ltd. Country or region before: China |